Ionis Cuts 2026 TRYNGOLZA Sales Forecast
Ionis Pharmaceuticals announced on November 9 that it was cutting its 2026 sales forecast for TRYNGOLZA. Kehoe Law Firm said it is investigating whether the company adequately disclosed adverse sales trends and commercialization challenges.
Kehoe Law Firm announced an investigation into Ionis Pharmaceuticals on behalf of investors following the company's November 9, 2026, announcement that it was cutting its 2026 sales forecast for TRYNGOLZA. The investigation seeks to determine whether Ionis adequately disclosed adverse sales trends and commercialization challenges known to management during the third quarter. The firm is inviting investors who suffered financial losses to contact them for a potential evaluation of legal claims.